By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


SEARCH JOBS








Company News
Boehringer Ingelheim Release: New Analysis Shows Idarucizumab Enables Rapid Initiation Of Emergency Surgery In Dabigatran-Treated Patients 9/1/2015 9:41:28 AM
FDA Warns Merck & Co. (MRK), AstraZeneca PLC (AZN) and Boehringer Ingelheim About Joint Pain With Diabetes Drugs 9/1/2015 7:03:27 AM
ESC Launches New Concept For Driving Innovation In Cardiovascular Research With Exclusive Support From Boehringer Ingelheim 8/31/2015 11:25:24 AM
Boehringer Ingelheim Release: U.S. FDA Approves Synjardy (empagliflozin/metformin hydrochloride) Tablets For Adults With Type 2 Diabetes 8/27/2015 9:07:12 AM
Boehringer Ingelheim Upgrades To Massively Scalable Innovopoint 6.6 For Enterprise Scalable Clinical And Investigator Portal Solution 8/20/2015 10:24:46 AM
Boehringer Ingelheim Release: Jardiance Demonstrated Cardiovascular (CV) Risk Reduction In People With Type 2 Diabetes At High Risk For CV Events 8/20/2015 8:47:05 AM
Boehringer Ingelheim Release: CHMP Recommends Label Update For Giotrif With Addition Of Data Demonstrating Overall Survival Benefit For Patients With EGFR Mutation-Positive Lung Cancer 8/19/2015 11:30:49 AM
Boehringer Ingelheim Release: New Data Show Spiolto Respimat Provides Meaningful Quality Of Life Improvements In COPD 8/17/2015 10:59:46 AM
Week In Review: Boehringer Ingelheim Signs $730 Million Deal For Hanmi Pharma SCLC Drug 8/3/2015 9:09:47 AM
First U.S. Patients Enroll In Boehringer Ingelheim's Global RE-DUAL PCI And RE-CIRCUIT Trials Evaluating Pradaxa (Dabigatran Etexilate Mesylate) 7/30/2015 10:29:11 AM
12345678910...
//-->